MET Amplification and Efficacy of Nivolumab in Patients With NSCLC

Introduction: MET amplification is an important genetic alteration in NSCLC. Unlike in patients with EGFR and ALK alterations, the efficacy of immune checkpoint inhibitors in patients with MET-amplified NSCLC remains unknown. Methods: An exploratory analysis of a prospective, multi-institutional coh...

全面介紹

書目詳細資料

Principais autores:	Katsuhiro Yoshimura, MD, PhD, Yusuke Inoue, MD, PhD, Naoki Inui, MD, PhD, Masato Karayama, MD, PhD, Hideki Yasui, MD, PhD, Hironao Hozumi, MD, PhD, Yuzo Suzuki, MD, PhD, Kazuki Furuhashi, MD, PhD, Tomoyuki Fujisawa, MD, PhD, Noriyuki Enomoto, MD, PhD, Yutaro Nakamura, MD, PhD, Haruhiko Sugimura, MD, PhD, Takafumi Suda, MD, PhD
格式:	Artigo
語言:	Inglês
出版:	Elsevier 2021-11-01
叢編:	JTO Clinical and Research Reports
主題:	Lung cancer MET Nivolumab Amplification Immune checkpoint inhibitor
在線閱讀:	http://www.sciencedirect.com/science/article/pii/S2666364321000989
標簽:	添加標簽 沒有標簽, 成為第一個標記此記錄!